Saturday 17 October 2026
Export CDNA’s income statement to Excel — free account
CareDx, Inc.
CDNA Healthcare Diagnostics & Research
CareDx, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $379.8 million, up 13.8% from fiscal 2024. In the quarter to June 2026, revenue grew 52.2%, EPS grew 1,443.8% and free cash flow grew 223.4%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
63.81
2.87
−4.30%
Follow CDNA
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
5 | 7 | 2 | 2 | 4 | 6 | 5 | 6 | 2 | 3 |
P/E ratio |
0.00 | 21.19 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
4.14 | 5.83 | (0.38) | 2.88 | 14.31 | 21.89 | 7.86 | 12.88 | (3.80) | (4.71) |
P/S ratio |
2.64 | 3.39 | 2.29 | 1.84 | 8.02 | 17.52 | 7.16 | 11.70 | 3.40 | 0.93 |
P/FCF ratio |
29.06 | 38.08 | 0.00 | 0.00 | 0.00 | 153.61 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(0.76) | 3.44 | (3.02) | 4.08 | 6.42 | 3.31 | (4.68) | (2.59) | (13.42) | (13.15) |
P/Operating CF |
46.99 | 51.62 | (76.60) | 82.38 | 570.31 | 468.96 | (839.53) | 448.43 | (76.51) | (12.40) |
Beneish M-Score |
(3.36) | (2.23) | (4.44) | (2.78) | (1.91) | (2.86) | (2.10) | (2.40) | (4.85) | (3.36) |
P/B ratio |
3.31 | 2.99 | 2.46 | 1.37 | 5.10 | 12.13 | 9.18 | 9.34 | 0.00 | 1.92 |
Price to Tangible BV |
4.35 | 3.77 | 3.66 | 1.69 | 6.27 | 16.08 | 30.71 | 17.68 | 0.00 | 0.00 |
EV/Sales |
2.18 | 2.61 | 1.46 | 0.94 | 6.85 | 16.44 | 6.86 | 11.04 | 3.76 | 1.10 |
EV/EBITDA |
0.00 | 14.26 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
19.73 | 22.91 | (22.24) | (11.93) | (105.21) | 94.51 | (314.74) | (210.93) | (12.70) | (2.70) |
EV/FCF |
24.00 | 29.38 | (14.29) | (6.08) | (51.32) | 144.12 | (120.34) | (139.89) | (12.53) | (2.61) |
Quick Ratio |
2.45 | 3.64 | 3.67 | 4.73 | 5.28 | 3.75 | 1.79 | 3.81 | 0.46 | 0.49 |
Current Ratio |
2.86 | 3.94 | 4.02 | 5.11 | 5.61 | 3.95 | 2.07 | 4.16 | 0.62 | 0.65 |
Net Debt/EBITDA |
19.49 | (4.26) | 1.25 | 4.82 | 20.85 | 17.31 | 2.20 | 7.26 | (1.35) | (0.22) |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 40.76% | 31.21% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (5.72) | 1.21 |
Asset Turnover |
0.84 | 0.70 | 0.56 | 0.58 | 0.63 | 0.74 | 0.90 | 0.71 | 0.60 | 0.61 |
Operating CF/Net income |
(1.97) | 0.72 | 0.10 | 0.33 | 0.63 | (1.79) | 0.13 | 0.09 | 0.26 | 0.42 |
Capex/Depreciation |
(0.30) | (0.32) | (0.62) | (1.48) | (1.56) | (1.09) | (0.47) | (1.08) | (0.02) | (0.08) |
Interest Coverage |
— | — | — | (20.53) | (185.79) | (83.13) | (24.91) | (4.21) | (3.46) | (20.07) |
| (6.27%) | 16.43% | (54.98%) | (17.09%) | (8.25%) | (9.94%) | (22.54%) | (103.93%) | (803.49%) | (160.26%) | |
| (4.72%) | 10.97% | (37.69%) | (13.81%) | (6.56%) | (7.19%) | (15.56%) | (43.64%) | (69.21%) | (59.64%) | |
ROIC |
(15.28%) | 21.63% | (490.55%) | (35.02%) | (15.83%) | (26.58%) | (25.23%) | (31.09%) | (113.15%) | (88.22%) |
Return on Tangible Assets |
(10.66%) | 17.75% | (70.24%) | (22.05%) | (8.11%) | (8.72%) | (52.90%) | (71.12%) | 394.40% | 351.52% |
Average Days of Receivables |
40.97 | 70.65 | 66.48 | 75.22 | 73.59 | 65.76 | 69.10 | 46.53 | 22.59 | 24.87 |
Research and Development Expense of Revenue |
18.81% | 21.72% | 29.40% | 28.09% | 25.82% | 25.46% | 24.17% | 18.96% | 25.64% | 30.48% |
Selling, General and Administrative Expense of Revenue |
55.35% | 62.05% | 72.38% | 61.04% | 51.35% | 53.42% | 59.37% | 58.31% | 68.08% | 78.49% |
Intangible Assets out of Total Assets |
0.18 | 0.16 | 0.18 | 0.15 | 0.15 | 0.19 | 0.46 | 0.35 | 0.54 | 0.61 |
Share Based Compensation of Revenue |
9.18% | 19.89% | 17.51% | 14.47% | 12.17% | 12.18% | 17.64% | 9.32% | 3.61% | 4.92% |
Graham Net Nets |
0.15 | 0.21 | 0.17 | 0.47 | 0.14 | 0.05 | 0.02 | 0.05 | (0.38) | (0.80) |
Graham Number |
0.00 | 12.77 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.56 | 0.00 |
Earnings Yield |
(2.12%) | 4.72% | (29.65%) | (12.97%) | (1.30%) | (0.58%) | (2.41%) | (5.29%) | (31.35%) | (108.65%) |
Free Cash Flow Yield |
3.44% | 2.63% | (4.46%) | (8.38%) | (1.66%) | 0.65% | (0.80%) | (0.67%) | (8.81%) | (44.99%) |
Revenue per Share |
7.13 | 6.32 | 5.21 | 6.03 | 5.67 | 4.13 | 3.01 | 2.15 | 2.07 | 2.46 |
Operating CF per Share |
0.79 | 0.72 | (0.34) | (0.47) | (0.37) | 0.72 | (0.07) | (0.11) | (0.61) | (1.00) |
Capex per Share |
(0.12) | (0.12) | (0.17) | (0.46) | (0.39) | (0.22) | (0.08) | (0.20) | (0.01) | (0.03) |
Free Cash Flow per Share |
0.67 | 0.60 | (0.51) | (0.93) | (0.76) | 0.50 | (0.15) | (0.32) | (0.62) | (1.03) |
Cash per Share |
3.33 | 4.94 | 4.38 | 5.50 | 6.67 | 4.83 | 0.91 | 1.81 | 0.72 | 1.05 |
Shareholders Equity per Share |
5.69 | 7.17 | 4.86 | 8.08 | 8.92 | 5.97 | 2.35 | 2.69 | (0.26) | 1.20 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
5.69 | 7.17 | 4.86 | 8.08 | 8.92 | 5.97 | 2.35 | 2.69 | (0.26) | 1.20 |
Free Cash Flow |
35.44 | 31.56 | (27.63) | (49.57) | (39.55) | 23.07 | (6.12) | (11.24) | (14.49) | (17.07) |
Working Capital |
167.28 | 262.46 | 235.64 | 311.87 | 356.06 | 203.88 | 37.09 | 61.61 | (16.14) | (14.16) |
Capital Expenditures |
(6.59) | (6.48) | (9.24) | (24.33) | (20.26) | (10.36) | (3.35) | (7.24) | (0.19) | (0.55) |
Net Current Asset Value |
147.01 | 239.22 | 108.22 | 275.77 | 332.62 | 182.27 | 19.19 | 46.35 | (62.75) | (30.30) |
EV/EBIT |
0.00 | 21.38 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.02 | 0.02 | 0.03 | 0.08 | 0.07 | 0.05 | 0.03 | 0.09 | 0.00 | 0.01 |
Price to Operating Income |
0.00 | 27.72 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.66 | 0.61 | 0.42 | 0.46 | 0.59 | 0.89 | 1.61 | 1.62 | 3.66 | 2.37 |
Cash ROIC |
7.38% | 4.94% | (5.56%) | (6.85%) | (4.86%) | 4.59% | (4.46%) | (7.00%) | (32.21%) | (28.00%) |
Accounts Receivable Turnover |
7.08 | 5.77 | 4.78 | 5.10 | 6.28 | 6.55 | 7.52 | 12.01 | 16.78 | 15.83 |
Accounts Payable Turnover |
13.95 | 10.67 | 8.95 | 9.64 | 8.47 | 8.33 | 8.90 | 8.14 | 6.62 | 8.97 |
Inventory Turnover |
5.33 | 5.63 | 5.27 | 6.16 | 7.16 | 7.88 | 8.30 | 6.30 | 3.89 | 6.78 |
Average Days of Payables |
29.58 | 25.57 | 46.03 | 32.34 | 49.99 | 55.82 | 44.21 | 52.13 | 57.92 | 52.96 |
Days of Inventory on Hand |
79.09 | 64.89 | 69.63 | 62.56 | 64.41 | 57.90 | 48.29 | 54.69 | 94.43 | 94.37 |
Average Receivables |
53.62 | 57.83 | 58.69 | 63.04 | 47.19 | 29.34 | 16.91 | 6.38 | 2.88 | 2.57 |
Average Payables |
8.84 | 10.28 | 11.41 | 11.64 | 11.50 | 7.58 | 5.11 | 4.05 | 3.23 | 2.35 |
Average Inventory |
23.10 | 19.49 | 19.35 | 18.21 | 13.60 | 8.01 | 5.48 | 5.24 | 5.50 | 3.11 |
Average Assets |
452.14 | 478.94 | 504.91 | 554.81 | 467.57 | 260.12 | 141.22 | 107.13 | 80.15 | 66.18 |
Average Common Equity |
340.77 | 319.88 | 346.12 | 448.39 | 371.78 | 188.34 | 97.46 | 44.99 | 6.90 | 24.63 |
Columns are period end dates